Immune-Mediated Lesions of the Oral Cavity Murtaza Kharodawala, MD Faculty Advisor: Matthew Ryan, MD Grand Rounds Presentation The University of Texas Medical Branch Department of Otolaryngology April 26, 2006
Introduction • Oral cavity lesions are a common presenting complaint in Otolaryngology • Immune mediated lesions of the oral cavity may involve other sites and may be lifethreatening – Acute, chronic and/or recurrent vesicle, bullae, erosion/ulceration of oral cavity
Overview • • • • •
Lichen Planus Mucous Membrane Pemphigoid Bullous Pemphigoid Pemphigus Vulgaris Linear IgA Disease
Definitions • Vesicle: circumscribed collection of free fluid up to 0.5 cm in diameter
• Bulla: circumscribed collection of free fluid greater than 0.5 cm in diameter
Definitions • Erosion: a focal loss of epidermis which does not include the dermoepidermal juction. Heals without scar. • Ulcer: focal loss of epidermis and dermis. Heals with scar.
Definitions • Direct immunofluorescence: Labelled antibodies are used for detection of specific antigens • Indirect immunofluorescence: Labelled antibodies (to other antibodies) are used for detection of antibody-antigen complex
• Activation of inflammatory cascade by cellmediated means and/or antibody deposition and complex formation with antigen – Chemotaxis – Complement activation – Leukocyte Degranulation • Proteolytic enzymes that destroy the basement membrane, resulting in separation of the epidermis and dermis
Diagnosis: Biopsy!
Lichen Planus • Idiopathic inflammatory disorder of skin and mucous membranes • Mucosal disease may occur without cutaneous involvement – – – –
Present in sixth decade F:M 2:1 Greater than half involve oral cavity, mostly on buccal mucosa Asymptomatic or painful
• Pathogenesis: – May be T-cell mediated immune response to unknown cause – No autoantibodies found – IgG, IgM, IgA, and complement deposition as well as fibrin and fibrinogen present in BMZ
Lichen Planus • Clinical Features: – Classified as reticular, plaque-like, atrophic, papular, erosive, and bullous • Reticular: appear dendritic, lacy, in a white arborizing pattern with or without erythema and ulceration
– Wickhams striae: whitish lines of epidermal thickening – Negative Nikolsky sign: pressure over lesion does not result in extension of fluid into surrounding normal epidermis/mucosa – Koebner phenomenon: lesions develop in previous sites of trauma – Malignant transformation to oral SCCA in 0.8%
Lichen Planus Reticular, lace-like pattern
Lichen Planus
From: Eisen: Oral Diseases, 11(6).November 2005.338-349
Lichen Planus Atrophic
Lichen Planus Erythematous LP with reticular pattern
From: Eisen: Oral Diseases, 11(6).November 2005.338-349
Lichen Planus • Erosive
Lichen Planus • Erosive
From: Eisen: Oral Diseases, 11(6).Novermber 2005.338-349
Lichen Planus Desquamative gingivitis
From: Eisen: Oral Diseases, 11(6).Novermber 2005.338-349
Lichen Planus • Diagnosis – Clinical – Biopsy!
Lichen Planus • Histology: – Loss of rete pegs, epidermal thickening, lymphocytic infiltration
Lichen Planus • Direct immunofluorescence: – Ovoid deposits of IgG, IgA, IgM, and complement in BMZ
From: Immunodermatology Test Result Images, University of Utah Health Sciences Center website, April 18, 2006.
Lichen Planus • Usually self limited (8-12 months) • 50% may recur • Medical Therapy – Topical, intralesional, and systemic steroids • Triamcinolone (orabase) • Intralesional methylpred (20-40mg) • Oral prednisone (recurrence when tapered)
– Dapsone (50-150 mg daily) – Resistant, debilitating disease: • • • •
Plaquenil Azathioprine Isotretinoin Acitretin
Bullous Pemphigoid • Autoimmune bullous disease generally in the elderly – Most occurs after 60 years of age
• Pathophysiology – Antibodies (IgG) to bullous pemphigoid antigens 230 (cytoplasmic) and 180 (transmembrane) of basal cell desmosomes – IgG found circulating and bound within lamina lucida
Bullous Pemphigoid • Clinical Features: – Oral blisters (24%) – Localized erythema or urticarial plaque which advances to form tense bullae – Negative Nikolsky sign: Firm pressure on the blister will not result in extension into normal skin – Generalized: abdomen, groin, flexor surfaces, palms and soles – Erode within a week to leave eroded bases – Heals rapidly (unlike pemphigus) – May be associated with trauma, radiation, vaccination, and systemic medications (furosemide, diazepam, spironolactone) – No increased risk of malignancy – Vesicular, vegetative, generalized erythroderma, urticarial, and nodular variants
Bullous Pemphigoid
Bullous Pemphigoid Cutaneous tense bullae
Bullous Pemphigoid • Diagnosis: – Circulating eosinophilia – Elevated serum IgE – Biopsy!
Bullous Pemphigoid Histology: Cleavage between epidermal and dermal junction with presence of eosinophils and to a lower extent neutrophils
Bullous Pemphigoid
Bullous Pemphigoid
Direct Immunofluorescence and Electron Microscopy IgG and/or C3, and to lesser extent IgA, IgM, and fibrin present in a linear fashion at the BMZ
Bullous Pemphigoid Indirect Immunofluorescence
Bullous Pemphigoid • Untreated BP may remain localized and undergo spontaneous remission or become generalized • Generalized BP has poor prognosis – Mortality at 1 year up to 19% with treatment – Mortality without treatment 24% – Remission: 30% at 2 years, 50% at 3 years
Bullous Pemphigoid • Medical Therapy – – – – – – – – – – – – – –
Antibiotics: tetracyline, erythromycin Topical steroids (Clobetasol propionate cream 0.05%) Systemic steroids (Prednisone 0.5-1 mg/kg/day) Dapsone (50-200 mg/day) Sulfapyridine (500-1500 mg/day) Azathioprine (1-2.5 mg/kg/day) Mycophenolate Mofetil (0.5-1 gm twice daily) Cyclophosphamide Methotrexate (5-12.5 mg/week) Cyclosporine Tacrolimus Chlorambucil IVIG Plasmapheresis
Mucous Membrane Pemphigoid • AKA Cicatricial Pemphigoid • Autoimmune blistering disease resulting in ulceration and often scarring – Variant of localized pemphigoid – Adults 40-60 years – Female to male 2:1 ratio
• Pathophysiology: – – – – –
Autoantibodies to antigens within the lamina lucida of the BMZ Bullous pemphigoid hemidesmosomal antigen 180 BPAG2 Laminen 5 β 4 Integrin subunit
Mucous Membrane Pemphigoid • Clinical Features: – Oral cavity (85%) and eyes (65%) are most common sites involved – Gingiva (90%), palate, less often buccal mucosa – Characterized by erythema, painful vesicle or bullae formation followed by rupture leaving ulcers – Negative Nikolsky sign – Ulcers heal in 7-10 days – Vermilion not involved (in contrast to pemphigus) – Laryngeal involvement (8%) – Hoarseness – Ocular manifestations: • • • • •
Conjunctivitis to blindness Corneal ulceration, opacification Fibrous conjuctival adhesions (fixed globe) Decreased tearing Blindness in up to 20% affected
– Skin lesions (25%): face, neck scalp, genetalia
Mucous Membrane Pemphigoid
Mucous Membrane Pemphigoid
Mucous Membrane Pemphigoid
Mucous Membrane Pemphigoid
Mucous Membrane Pemphigoid Laryngeal Stenosis
From: Boedeker: Ann Otol Rhinol Laryngol. 112(3): Mar 2003: 271-275
Mucous Membrane Pemphigoid
Mucous Membrane Pemphigoid
Mucous Membrane Pemphigoid • Diagnosis: – Biopsy!
Mucous Membrane Pemphigoid Histology: Separation of epithelium from underlying tissue at lamina lucida *Pemphigus has cleavage at the spinous layer of epithelium
Mucous Membrane Pemphigoid Direct immunofluorescence: Linear deposits of IgG, IgA, and C3 at BMZ in continuous pattern
Mucous Membrane Pemphigoid • Medical Therapy – – – – – – – – –
Debridement and wound care Dexamethasone elixir oral rinse Fluconinide gel Triamcinolone (Orabase) Intralesional (5-10 mg/ml) and systemic steroids (prednisone 0.75-1 mg/kg/day) Dapsone (75-200 mg daily) Cyclophosphamide (1.5-2.5 mg/kg/day) Mitomycin C Tacrolimus
Mucous Membrane Pemphigoid • Medical Therapy – IVIG – Plasmapheresis – Eyes: lubrication and antibiotic gtt
• Surgical Intervention – May be needed in cases involving the eyes, larynx, and esophagus due to scarring • Blindness • Laryngeal stenosis • Esophageal stricture
– Ideally when disease is in remission
Pemphigus Vulgaris • Autoimmune bullous disease of skin and mucous membranes – Related to pemphigus foliaceus (differs by level of acantholysis in epithelium) – Other members of pemphigus family are paraneoplastic pemphigus (lymphoma) and druginduced pemphigus (penicillamine)
• 1-5 cases per million per year – Onset in sixth decade – M=F
Pemphigus Vulgaris • Pathophysiology: – Genetically predisposed individuals and exogenous factor (antigen mimicking desmosomal protein) – Autoantibodies that bind to desmosomal components resulting in acantholysis – Cell-cell adhesion • Desmoglein 1, Dsg1 (skin) • Desmoglein 3, Dsg3 (oral and skin)
Pemphigus Vulgaris • Clinical Features – Mucosal involvement in 50% • Soft palate 80% • Eye • Esophageal mucosa
– Painful oral erosions preceding skin blisters • Scalp, face, axilla
– If untreated, become generalized – Positive Nikolsky sign: pressure over intact bullae results in fluid dissection laterally into the surrounding midepidermis – Erosions last for weeks before healing with brownish hyperpigmentation – Associated with Myasthenia gravis and thymoma
Pemphigus Vulgaris Collapsed bullae over buccal mucosa
Pemphigus Vulgaris
Pemphigus Vulgaris
Pemphigus Vulgaris Erosive gingivitis
Pemphigus Vulgaris
Pemphigus Vulgaris
Pemphigus Vulgaris Conjunctival and scleral involvement
Pemphigus Vulgaris • Diagnosis: – Biopsy!
Pemphigus Vulgaris Histology: Intraepidermal bulla and acantholysis with detachment of basal cells from each other but still attached to BMZ. Moderate eosinophil infiltration
Pemphigus Vulgaris
Pemphigus Vulgaris
Pemphigus Vulgaris Direct Immunofluorescence: IgG against Dsg3 present in intercellular space in stratum spinosum
Pemphigus Vulgaris • •
Avoid sunlight Mortality high if untreated (50% at 2 years, 100% at 5 years) – With treatment 10%
•
Medical Therapy: – *Oral steroids (Prednisone 0.5-1 mg/kg/day) – Topical steroids (Clobetasol propionate 0.05% BID) – Cyclophosphamide 1.5 mg/kg/day (most effective) • Bone marrow suppression, hemorrhagic cystitis, bladder fibrosis and carcinoma, lymphoma
– Azathioprine 1.5-2.5 mg/kg/day • Bone marrow suppression, hepatotoxic, malignancy
– – – – – – –
•
IVIG monotherapy or as adjuvant Chlorambucil Mycophenolate mofetil Dapsone Cyclosporine Tetracycline May stop when clinically free of disease and negative direct immunofluorescence
Remission in 75% after 10 years
Linear IgA Disease •
Acquired or idiopathic, autoimmune, blistering disorder – Incidence 0.6 per 100,000 – 2:1 Female to male ratio
•
Two clinical types: (share histologic and immunologic findings) – Chronic dermatosis of childhood in first decade – Adult linear IgA disease, peak 60-65 years
•
Pathophysiology: – Resembles Dermatitis Herpetiformis – IgA deposits below lamina densa of BMZ or within the lamina lucida, or both – Multiple antigens with multiple binding sites on each antigen – Bullous pemphigoid antigen BP180 and extracellular domain LAD1 – Gluten sensitivity in 25-33% – Associated with RA, UC, immune glomerulonephritis, malignancy – Drugs, including Vancomycin
Linear IgA Disease • Clinical Features: – Vesiculobullous lesions may be present over entire body including oral mucosa and conjuctiva – Lesions may be painful and/or pruritic – Negative Nikolsky sign
Linear IgA Disease Desquamative Gingivitis
From: ORegan: Arch Otolaryngol Head Neck Surg, 130(4).April 2004.469–472
Linear IgA Disease Buccal Ulceration
From: ORegan: Arch Otolaryngol Head Neck Surg, 130(4).April 2004.469–472
Linear IgA Disease Ocular Findings: conjunctivitis, fibrosis, scarring
From: Klein: Linear IgA Dermatosis. Emedicine, Jun 23, 2003.
Linear IgA Disease • Diagnosis – Elevated ESR and circulating IgA – Biopsy!
Linear IgA Disease Histology: Separation of the epidermis and dermis with eosinophils in subepithelial split
From: ORegan: Arch Otolaryngol Head Neck Surg, 130(4).April 2004.469–472
Linear IgA Disease Direct Immunofluorescence: Linear subepithelial band of IgA deposition
From: ORegan: Arch Otolaryngol Head Neck Surg, 130(4).April 2004.469–472
Linear IgA Disease • Medical Therapy – Topical and systemic steroids (usually not effective) – Dapsone 25-150 mg daily • Peripheral Motor Neuropathy • Hemolytic Anemia
– Sulfapyridine 500-1500 mg daily – Colchicine, Tetracylcine, Nicotinamide
• Many cases resolve spontaneously
Biopsy site
Bx by DIF
Serum by IDIF
Lichen Planus
Edge of involved skin
Mult Ig, C, fibrin in cytoid bodies in epidermis with fibrin around rete pegs
None
Bullous Pemphigoid
Erythematous perilesional skin
IgG and/or C3 in BMZ found in linear pattern
IgG in BMZ
Mucous Membrane Pemphigoid
Erythematous perilesional skin
IgG and/or C3 in BMZ in linear pattern
IgG and IgA in BMZ
Pemphigus
Erythematous perilesional skin
IgG in Intercellular area of stratum spinosum
Mult antibodies in stratum spinosum
Perilesional skin
IgG and/or C3 at BMZ in linear pattern
IgA in BMZ
Disorder
Linear IgA
Bibliography Habif: Clinical Dermatology, 4th ed., Copyright © 2004 Mosby, Inc. Cummings: Otolaryngology: Head & Neck Surgery, 4th ed., Copyright © 2005 Mosby, Inc. Eisen et al. Oral lichen planus: clinical features and management. Oral Diseases 2005;11:338349. Boedeker et al. Cicatricial pemphigoid in the upper aerodigestive tract: diagnosis and management in severe laryngeal stenosis. Ann Otol Rhinol Laryngol 2003;112:271-275. Sacher et al. Cicatricial pemphigoid. Am J Clin Dermatol 2005;6:93-103. O’Regan et al. Linear IgA disease presenting as desquamative gingivitis. Arch Otolaryngol Head and Neck Surgery 2004;130:469-472. Ruocco et at. Life-threatening bullous dermatoses: pemphigus vulgaris. Clinics in Dermatol 2005;23:223-226. Yeh et al. Blistering disorders: diagnosis and treatment. Dermatol Therapy 2003;16:214-223. Kirtschig et al. Management of Bullous Pemphigoid. Am J Clin Dermatol 2004;5:319-326.